Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alglucosidase alfa in Late-Onset Pompe Disease (Extension Study)
NCT00455195Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
Phase 4, open-label trial of alglucosidase alfa in Pompe disease (2 arms), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events at 2.5 years, Six-Minute Walk Test at 104 weeks and 1 more. Started Mar 2007; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00455195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455195.